An Exploratory, Multi-cohort Phase II Study of combination therapy of AK112 with chemotherapy and/or olaparib in platinum-sensitive ovarian cancer(PSOC)
Signs the written informed consent form.
Female participants who are at least 18 years of age on the day of signing informed consent with.
ECOG of 0 or 1.
Life expectancy ≥3 months.
Other pathological types such as mucinous cancer, sex cord stromal cell tumor, etc.
Presence of central nervous system (CNS) metastases or carcinomatous meningitis.
Subjects with uncontrollable pleural, pericardial, or peritoneal effusion requiring repeated drainage.
Subjects with other active malignancies within 3 years prior to randomization.